| Name | Title | Contact Details |
|---|
Aprecia, The 3DP Pharmaceutical Company, expects to use its ZipDose® Technology to transform the way people take medicine. Its first innovation, ZipDose Technology can be combined with a wide variety of active pharmaceutical ingredients to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Aprecia is committed to enhancing the patient experience through novel approaches to drug delivery that address unmet treatment needs to eliminate patient suffering and caregiver burden.
Virtual Radiologic Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Virtual Radiologic Corporation is based in Eden Prairie, MN. You can find more information on Virtual Radiologic Corporation at www.virtualrad.com
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares are expected to begin trading on the TSX-V on March 3, 2014 under the symbol GUD.
Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps is a non-profit integrated health care delivery system based in San Diego, Calif. We treat more than 700,000 patients annually through the dedication of 3,000 affiliated physicians and more than 15,000 employees among our five acute-care hospital campuses, hospice and home health care services, 27 outpatient centers and clinics, and hundreds of affiliated physician offices throughout the region. Medical Excellence Every Step of the Way Recognized as a leader in disease and injury prevention, diagnosis and treatment, Scripps has been ranked four times as one of the nation`s best health care systems by Truven Health Analytics. Our hospitals are consistently ranked by U.S. News & World Report among the nation`s best – and Scripps is regularly recognized by Fortune, Working Mother magazine and The Advisory Board as one of the best places in the nation to work. Scripps is also at the forefront of clinical research, genomic medicine and wireless health care. With three highly respected graduate medical education programs, Scripps is a longstanding member of the Association of American Medical Colleges.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.